Foghorn Therapeutics Inc.
Ticker: FHTX
| Insider | Title |
|---|---|
| Adam Koppel | Director |
| Adrian Gottschalk | Chief Executive Officer, Director |
| Alfonso Quintas Cardama | Chief Medical Officer |
| Allan Reine | Chief Financial Officer |
| Anna Rivkin | Chief Business Officer |
| B Lynne Parshall | Director |
| Carl Decicco | Chief Scientific Officer |
| Carlos Costa | Chief People Officer |
| Cigall Kadoch | Director |
| Douglas G. Cole | Director |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer |
| Ian F Smith | Director |
| Kristian Humer | Chief Financial Officer |
| Michael Lacascia | Chief Legal Officer |
| Michael Mendelsohn | Director |
| Noubar Afeyan | 10% or greater ownership |
| Pioneering Fund Vii General Partner Llc Flagship | 10% or greater ownership |
| Pioneering Fund Vii, L.p. Flagship | 10% or greater ownership |
| Pioneering Inc. Flagship | 10% or greater ownership |
| Pioneering Special Opportunities Fund Ii General Partner Llc Flagship | 10% or greater ownership |
| Pioneering Special Opportunities Fund Ii, L.p. Flagship | 10% or greater ownership |
| Samuel Agresta | Chief Medical Officer |
| Scott Biller | Director |
| Simba Gill | Director |
| Steven F. Bellon | Chief Scientific Officer |
| Thomas J. Jr. Lynch | Director |